Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease
作者： Jessica Kendrick , Michel Chonchol
DOI: 10.1111/SDI.12412
关键词: Medicine 、 Pathology 、 Intensive care medicine 、 Secondary hyperparathyroidism 、 Hyperphosphatemia 、 Disease 、 Disease management (health) 、 Complication 、 Survival rate 、 End stage renal disease 、 Fibroblast growth factor 23
摘要: Abnormalities in mineral metabolism are a universal complication dialysis patients and associated with an increased risk of cardiovascular disease mortality. Hyperphosphatemia, fibroblast growth factor 23 levels secondary hyperparathyroidism all strongly adverse outcomes end stage renal (ESRD) most treatment strategies target these parameters. Over the past few years, new therapies have emerged for abnormalities ESRD many promising. This article will review therapeutic options including potential advantages disadvantages compared to existing therapies.
sci-hub.se 参考文章(51)
Hsin-Hung Lin, Hung-Hsiang Liou, Ming-Shiou Wu, Ching-Yuang Lin, Chiu-Ching Huang, Long‐term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients Nephrology. ,vol. 19, pp. 672- 678 ,(2014) , 10.1111/NEP.12319
Jordi Bover, Lloret, Ruiz_Garcia, DaSilva, Furlano, Barreiro, Ballarin, Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherence. Patient Preference and Adherence. ,vol. 7, pp. 1147- 1156 ,(2013) , 10.2147/PPA.S31694
Jason Stubbs, Shiguang Liu, L. Darryl Quarles, Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Seminars in Dialysis. ,vol. 20, pp. 302- 308 ,(2007) , 10.1111/J.1525-139X.2007.00308.X
Mariano Rodríguez, Angel L M de Francisco, Magnesio y enfermedad renal crónica Nefrologia. ,vol. 33, pp. 389- 399 ,(2013) , 10.3265/NEFROLOGIA.PRE2013.FEB.11840
Takashi Shigematsu, Akihide Tokumoto, Akihisa Nakaoka, Hiroaki Arisaka, Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. Therapeutic Apheresis and Dialysis. ,vol. 15, pp. 176- 184 ,(2011) , 10.1111/J.1744-9987.2010.00898.X
James B. Wetmore, Shiguang Liu, Ron Krebill, Rochelle Menard, L. Darryl Quarles, Effects of Cinacalcet and Concurrent Low-Dose Vitamin D on FGF23 Levels in ESRD Clinical Journal of The American Society of Nephrology. ,vol. 5, pp. 110- 116 ,(2010) , 10.2215/CJN.03630509
Orlando M. Gutiérrez, Michael Mannstadt, Tamara Isakova, Jose Alejandro Rauh-Hain, Hector Tamez, Anand Shah, Kelsey Smith, Hang Lee, Ravi Thadhani, Harald Jüppner, Myles Wolf, Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. The New England Journal of Medicine. ,vol. 359, pp. 584- 592 ,(2008) , 10.1056/NEJMOA0706130
Geoffrey A. Block, David M. Spiegel, James Ehrlich, Ravindra Mehta, Jill Lindbergh, Albert Dreisbach, Paolo Raggi, Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis Kidney International. ,vol. 68, pp. 1815- 1824 ,(2005) , 10.1111/J.1523-1755.2005.00600.X
I. Tzanakis, A. Pras, D. Kounali, V. Mamali, V. Kartsonakis, D. Mayopoulou-Symvoulidou, N. Kallivretakis, Mitral annular calcifications in haemodialysis patients: a possible protective role of magnesium. Nephrology Dialysis Transplantation. ,vol. 12, pp. 2036- 2037 ,(1997) , 10.1093/NDT/12.9.2036
Eric Seibert, Gunnar H. Heine, Christof Ulrich, Sarah Seiler, Hans Köhler, Matthias Girndt, Influence of cholecalciferol supplementation in hemodialysis patients on monocyte subsets: a randomized, double-blind, placebo-controlled clinical trial. Nephron Clinical Practice. ,vol. 123, pp. 209- 219 ,(2013) , 10.1159/000354717